Aerie Pharma (AERI) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 4, 2021 4:01 PM EDTThird Quarter 2021 Net Revenues of $29.3 Million Increased 46% over Third Quarter 2020
 Third Quarter 2021 Net Revenue Per Bottle of $89, up 16% over Third Quarter 2020
Phase 3 Studies for AR-15512 and AR-1105 Expected to Begin in the First Half of 2022
Conference Call and Webcast Today, November 4th, at 5:00 p.m. ET
DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and... More
